Corbus Pharmaceuticals Holdings Inc’s recent filing unveils that its Officer Moran Sean F. acquired Company’s shares for reported $26468.0 on Feb 14 ’25. In the deal valued at $9.48 per share,2,792 shares were bought.
Then, Cohen Yuval bought 7,134 shares, generating $67,630 in total proceeds.
Before that, Cormorant Asset Management, LP bought 350,000 shares. Corbus Pharmaceuticals Holdings Inc shares valued at $7,003,761 were divested by the 10% Owner at a price of $20.01 per share. As a result of the transaction, Cormorant Asset Management, LP now holds 2,375,000 shares, worth roughly $20.21 million.
Piper Sandler initiated its Corbus Pharmaceuticals Holdings Inc [CRBP] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. B. Riley Securities started covering the stock on June 26, 2024. It rated CRBP as “a Buy”.
Price Performance Review of CRBP
On Friday, Corbus Pharmaceuticals Holdings Inc [NASDAQ:CRBP] saw its stock fall -10.23% to $8.51. Over the last five days, the stock has lost -16.16%. Corbus Pharmaceuticals Holdings Inc shares have fallen nearly -27.88% since the year began. Nevertheless, the stocks have fallen -61.32% over the past one year. While a 52-week high of $61.90 was reached on 01/16/25, a 52-week low of $8.50 was recorded on 02/14/25. SMA at 50 days reached $12.22, while 200 days put it at $32.62.
Levels Of Support And Resistance For CRBP Stock
The 24-hour chart illustrates a support level at 7.88, which if violated will result in even more drops to 7.24. On the upside, there is a resistance level at 9.28. A further resistance level may holdings at 10.04. The Relative Strength Index (RSI) on the 14-day chart is 34.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.76, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.99%. Stochastics %K at 20.90% indicates the stock is a holding.
How much short interest is there in Corbus Pharmaceuticals Holdings Inc?
A steep rise in short interest was recorded in Corbus Pharmaceuticals Holdings Inc stocks on 2025-01-31, dropping by 89715.0 shares to a total of 2.32 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 2.41 million shares. There was a decline of -3.87%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 03, 2024 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $80.
